Title : Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.

Pub. Date : 2019

PMID : 31105696






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Cell functional assays showed that Atezolizumab in combination with Bevacizumab inhibited the proliferation, migration, and invasion of cisplatin resistant ovarian cancer cell line A2780cis in vitro synergistically, which maybe associate with Bevacizumab suppressing the epithelial-mesenchymal transition (EMT) and PD-L1 expression by targeting STAT3. Cisplatin signal transducer and activator of transcription 3 Homo sapiens